Comparative Pharmacology
Head-to-head clinical analysis: LAROTID versus OXACILLIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAROTID versus OXACILLIN SODIUM.
LAROTID vs OXACILLIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) A, B, and C. It inhibits TRK kinase activity by binding to the ATP-binding site, leading to inhibition of downstream signaling pathways, which results in reduced cell proliferation and tumor growth in tumors with NTRK gene fusions.
Oxacillin is a penicillinase-resistant beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking the transpeptidation step in peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamase.
Larotrectinib 100 mg orally twice daily, with or without food, for adult patients.
1-2 grams IV every 4-6 hours.
None Documented
None Documented
30 minutes; prolonged in renal impairment (up to 20 hours in anuria).
0.3-0.8 hours in adults with normal renal function; prolonged to 1-2 hours in neonates and 2-5 hours in patients with severe renal impairment (CrCl <10 mL/min)
Renal: 70-80% unchanged by glomerular filtration and tubular secretion; Biliary/Fecal: <10% as inactive metabolites.
Renal (70-80% unchanged by tubular secretion and glomerular filtration); biliary (minor, approximately 10%)
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic